Vancomycin is a first-line agent in the treatment of serious Gram-positive infections in the neonatal population. The published evidence on vancomycin toxicity in neonates is limited. This review summarizes preclinical studies and clinical trials describing vancomycin toxicity. We discuss proposed pathophysiology and summarize evidence supporting dose-response relationships, genetic and environmental determinants, and consider future research required to further define vancomycin toxicity.
INTRODUCTION
Vancomycin is a glycopeptide bactericidal antibiotic that disrupts cell wall synthesis in Grampositive bacteria [1] . Impurities from early fermentation processes were associated with significant toxicity when the drug was first introduced in the early 1950s. The drug's poor safety profile, along with its thick brown appearance, led to the disparaging nickname 'Mississippi mud'. Refined purification methods improved the safety profile of vancomycin, and Food and Drug Administration approval was granted in 1958. Despite this, safety concerns lingered, leading to the drug's limited use. In recent decades, clinical use has increased, however, owing to the rising incidence of infections caused by methicillin-resistant Staphylococcus aureus and other resistant Gram-positive pathogens that are susceptible to vancomycin [2] .
Vancomycin dosing strategies vary greatly and are generally based on a combination of postmenstrual age, postnatal age, weight and/or renal function (see Table 1 ). Therapeutic drug monitoring is widely advocated. Currently, clinical guidelines recommend target trough concentrations of 10-15 mg/ ml [3, 4] . However, recent studies suggest the need for target trough levels less than 15 mg/ml, based on the concern that lower trough concentrations may be selective for hetero-resistance [5] [6] [7] . In adults, higher daily doses of vancomycin (15 mg/kg 6 hourly) have yet to receive regulatory approval but have been proposed in recent consensus documents published by the Infectious Diseases Society of America, the American Society of Health-System Pharmacists and the Society of Infectious Diseases Pharmacists [8] [9] [10] . The use of higher vancomycin doses has raised concerns regarding the potentially increased risk of toxicity. The significance of these concerns in paediatric populations is unclear. Here, we summarize the current evidence relating to vancomycin toxicity including proposed pathophysiology, dose-toxicity relationships, genetic and environmental factors and future research needs. Studies pertaining to vancomycin-induced toxicity between March 1950 and March 2015 were identified from PubMed, Embase, Cochrane Controlled Trial Registry and Medline databases. The following search terms were used 'vancomycin', 'toxicity', 'adverse effects', 'nephrotoxicity', 'kidney disease', 'renal impairment', 'ototoxicity', 'hearing loss', 'neonate', 'infant', 'child' and 'paediatrics'.
NEPHROTOXICITY

Quantification of nephrotoxicity
Kidney function is difficult to define in the first month of life when renal physiology and fluid balance evolve rapidly. Serum creatinine (SCr) concentrations reflect maternal renal function in the first 48 h after birth [11, 12] . In addition, preterm infants experience a rise in SCr due to tubular reabsorption, making this an imprecise proxy for glomerular filtration [13] . Clinical reports also often omit details of the laboratory methods used to quantify SCr (Jaffé colorimetry, enzymatic quantification or isotope dilution mass spectroscopy), which can have an intertest variability of up to 25% in neonates [14, 15] . Despite these limitations, most studies define renal impairment as an increase in SCr [16] [17] [18] [19] . Definitions for children and neonates have been reported based on several classification systems, all of which were originally developed and validated in adults [20, 21] . Modified neonatal criteria exclude urine output or use a higher cutoff (<1.0 ml/kg/h) in order to account for the nonoliguric renal dysfunction that occurs in neonates due to fluid redistribution and impaired absorption in the immature renal tubule [22,23 & ].
Preclinical studies
Murine models have demonstrated that vancomycin has an affinity for biological membranes and accumulates in renal tissue [24, 25] . The energydependent transport mechanisms within the tubular epithelium render the kidney highly susceptible to toxin-induced cellular injury. Vancomycin enhances cellular adenosine triphosphate concentrations and stimulates oxygen consumption, resulting in oxidative phosphorylation [26] [27] [28] [29] [30] [31] . However, oxidative stress of sufficient magnitude to cause clinically detectable renal impairment has not been demonstrated in animals, even at supratherapeutic doses [32] . Histopathological changes and biochemical evidence of nephrotoxicity have been observed in an uninfected murine model in which high-dose vancomycin was coadministered with tobramycin [25] .
Clinical studies
The linear relationship between SCr and vancomycin exposure reflects the drug's primary route of elimination through renal excretion. As a result, a decrease in renal function from any cause will increase serum vancomycin concentrations, a fact that confounds the establishment of exposuretoxicity relationships [33] . Many studies that describe vancomycin-associated nephrotoxicity are conducted in patients otherwise at risk of renal impairment, such as those requiring intensive care and frequently include those receiving other potentially nephrotoxic drugs (e.g. nonsteroidal anti-inflammatory drugs, diuretics and aminoglycoside antibiotics). However, irrespective of the difficulty in defining causal relationships, acute kidney injury from any cause is associated with a significantly increased risk of mortality, hospital length of stay and cost, even after adjustment for age, sex, chronic kidney disease and comorbidities at admission [34] .
Adult studies
Nephrotoxicity in patients receiving vancomycin has been more systematically reported in adults than in neonates and children. The reported incidence of nephrotoxicity in adults receiving vancomycin is 10-15% [35] . In a recent meta-analysis, van Hal et al. [36 && ] reviewed 15 studies in which vancomycin was administered via intermittent infusion to adults above 18 years of age. Randomized trials and observational studies in which data on renal function and trough vancomycin concentrations were available were included. The analysis found trough concentrations more than 15 mg/ml to be independently associated with an increased odds of nephrotoxicity (odds ratio, 2.67; 95% confidence interval, 1.95-3.65), and also suggested an incremental increase in nephrotoxicity risk with vancomycin administration beyond 7 days. The majority of reported cases were self-resolving, with prolonged impairment requiring short-term dialysis occurring in 3% of cases. Similarly, a retrospective cohort study of 246 adults receiving intermittent-dosing of vancomycin for durations of more than 48 h found toxicity to be correlated with exposure (based on dose). Patients receiving at least 4 g daily (n ¼ 26) had a significantly higher incidence of nephrotoxicity compared with those receiving less than 4 g daily (34.6 vs. 10.9%; P ¼ 0.001) [18] .
Concomitant aminoglycoside use has consistently been shown to increase the risk of nephrotoxicity in adults receiving vancomycin. In 2007, Fowler et al. [37] reported a seminal open-label randomized trial of daptomycin vs. either antistaphylococcal penicillin or vancomycin and low-dose gentamicin in 236 patients with S. aureus bacteremia. The highest proportion of renal impairment occurred in patients receiving vancomycin and gentamicin (20.4%), although this was not significantly higher than with penicillin and gentamicin (18.6%).
Furthermore, the study found that the highest incidence of renal impairment in patients receiving vancomycin occurred later in treatment, peaking at 14-28 days.
Paediatric and neonatal studies
Vancomycin administration with intermittent dosing and in accordance with published guidance has been shown to result in subtherapeutic trough concentrations in up to half of treated neonates [4] . Furthermore, antimicrobial point prevalence surveys that describe prescribing practices have demonstrated that significant variation in prescribing of vancomycin in neonates exists in clinical practice, with a large proportion of neonates receiving daily doses of vancomycin that are significantly below even the most conservative current recommendations [38 && ]. outlines the clinical studies that have reported nephrotoxicity associated with vancomycin use in neonates and infants. The majority of studies identified are heterogeneous observational or opportunistic pharmacokinetic studies based on routine therapeutic drug monitoring and are insufficiently powered to detect toxicity.
As with adults, cases of renal impairment are more frequently reported in neonates and children receiving concomitant nephrotoxic drugs [19, 35] . Eight of 10 studies describing concomitant nephrotoxic drugs alongside vancomycin therapy demonstrated evidence of renal impairment, which was mild and transient in all reported cases (see Table  2 ). Other reports have not found vancomycin to be an independent predictor of nephrotoxicity. Constance et al. [23 & ], for example, found no significant difference in the proportion of neonates developing nephrotoxicity in those receiving vancomycin and gentamicin (12 of 533, 2.2%) vs. those receiving gentamicin alone (seven of 533, 1.3%). Logistic regression demonstrated that while positive blood culture, low birth weight, patent ductus arteriosus, concomitant nonsteroidal anti-inflammatory drug use and illness severity were all independent risk factors for nephrotoxicity, vancomycin in conjunction with gentamicin was not. Six studies report rates of nephrotoxicity in neonates receiving vancomycin alone. A transient rise in SCr, microproteinuria and elevated N-acetyl-b-D-glucosamine was reported in only three, two and one patient, respectively (see Table 2 ) [51, 54, [59] [60] [61] . Exposure-toxicity relationships have not been clearly defined for vancomycin in neonates. Two case reports have described clinical outcomes in four neonates receiving accidental overdoses of up to 10fold the maximum recommended dose [51, 59] . All four patients developed transient renal impairment, though all had normal renal function at 6 months. It is noteworthy that these cases all involved single or brief exposures that were managed with immediate vancomycin withdrawal, and so these findings do not address the potential risk of cumulative exposure.
A number of recent studies have described the administration of vancomycin via continuous infusion in neonates. Continuous infusion has the theoretical advantage of maintaining constant plasma concentrations, meaning that overall drug exposure can be increased without a rise in peak concentrations. Studies investigating continuous vancomycin infusions in neonates have, to date, been based on studies that defined toxicity differently and involved small patient cohorts that received varied dosing regimens. A loading dose of 7-15 mg/kg was given in three studies. Collectively, the results of these studies suggest that continuous infusion may result in a higher proportion of patients achieving target concentrations between 15 and 20 mg/ml. Reported rates of nephrotoxicity do not differ significantly from those in patients receiving intermittent dosing, and there is currently no evidence to suggest the use of a loading dose that increases the risk of nephrotoxicity [3,45 & ,47,60] . Continuous infusions may, however, be impractical in the neonatal population where venous access is limited, and may lead to periods without effective antibiotic cover if access is lost. There have, as yet, been no systematic studies comparing the safety and efficacy of continuous infusion with high-dose intermittent regimens that specifically target trough concentrations of more than 15 mg/ml.
OTOTOXICITY
Quantification of ototoxicity in neonates
The assessment of hearing in infants is challenging. Behavioural tests (e.g. visual reinforcement audiometry) are the gold standard, but cannot be performed reliably in children below $8 months [67] . The methods currently employed to quantify auditory function in neonates are otoacoustic emissions (OAEs) and auditory brainstem responses (ABRs). Serial diagnostic OAE or ABR testing has been used to monitor ototoxicity in children receiving aminoglycosides [68] [69] [70] [71] . There are no equivalent reports describing serial OAE or ABR following vancomycin use. Diagnostic OAE or ABR is labourintensive and difficult to interpret in premature infants (postmenstrual age <34 weeks) due to immaturity of the cochlea and central auditory pathways [72] [73] [74] [75] [76] [77] [78] .
Universal newborn hearing screening (UNHS) uses a combination of automated OAE and ABR, and is designed to identify severe permanent hearing impairment in term neonates. Standardized UNHS programmes are now being implemented in the United States and Europe [79, 80] . UNHS is a single-point assessment and is not designed to detect and monitor subtle high-frequency hearing loss that typically occurs in drug-induced ototoxicity.
Preclinical studies
The association between vancomycin use and hearing impairment is controversial. As in the case of nephrotoxicity, the mechanism of vancomycininduced ototoxicity is thought to involve dosedependent intracellular oxidative damage, which leads to the loss of cochlear sensory hair cells resulting in high-frequency hearing loss [81] . Ototoxicity has not been consistently demonstrated with vancomycin in animal models [25, [82] [83] [84] . Studies in guinea pigs found no evidence of vancomycin ototoxicity, but found that vancomycin increases the probability of ototoxicity, measured by OAE, when coadministered with gentamicin [85] .
Clinical studies
The majority of vancomycin-associated ototoxicity was reported early in the drug's use in patients treated with indeterminate doses of an impure fermentation product who often received concomitant therapy with other severely ototoxic agents [86, 87] . Overall, the available recent literature on vancomycin-associated ototoxicity is heterogeneous and in many cases causation is uncertain.
Adult studies
Observational studies have suggested that the risk of ototoxicity may be increased with vancomycin doses at least 4 g daily in adults. In a retrospective study of 89 adults receiving more than 14 days of high-dose vancomycin, Forouzesh et al. [88] reported high-frequency hearing loss identified by pure-tone audiometry in 10 patients (12%), a rate significantly higher than reported at standard doses. However, the study included patients receiving concomitant aminoglycosides and diuretics, and identified no significant difference in mean trough vancomycin concentrations in patients with and without abnormal audiometry, suggesting the phenomenon was unlikely to be dose-dependent.
Paediatric and neonatal studies
Ototoxicity is infrequently reported in neonates and children treated with vancomycin in general [89] . Buckingham et al. [90] , however, reported a high incidence of hearing loss in children with pneumococcal meningitis treated with vancomycin. Patients aged 5-20 years (n ¼ 109) received vancomycin alongside a third-generation cephalosporin. Over half of those surviving had significant permanent hearing loss (n ¼ 37, 55%). Of note, hearing loss was independently associated with vancomycin administration within 2 h of presentation. Whether these findings apply to other populations or reflect the specific pathophysiology of pneumococcal meningitis is uncertain. The findings do, however, highlight the need to consider population and diseasespecific factors when reporting drug toxicity.
In neonates, reporting of vancomycin-associated ototoxicity comes almost exclusively from routine UNHS. De Hoog et al. [91] studied 625 neonates over 2 years from a single neonatal intensive care unit in the Netherlands. Exposure to vancomycin (alone or in combination with tobramycin or furosemide) was not associated with a significant rise in screening failure rates. Similarly, in a retrospective study of more than 7000 infants, Gopel et al. [92] found no association between vancomycin exposure and UNHS failure rates. Vella-Brincat et al. [93] described UNHS outcomes over 5 years from a single centre in New Zealand. The cohort included 41 neonates who received vancomycin, and found higher failure rates (n ¼ 6; 22%), compared with those not exposed to vancomycin (n ¼ 85/1,233; 7%). The significance of these findings is uncertain given the lack of systematic followup and many potential confounding factors.
CONCLUSION
Despite historical concerns, a large body of evidence now exists to support the favourable safety profile of vancomycin in humans. In adults, nephrotoxicity is exposure-dependent, and more aggressive dosing may result in a significantly increased risk of toxicity. By comparison, current dosing regimens in neonates are conservative, and result in subtherapeutic concentrations in a large proportion of patients. At present, insufficient evidence exists to inform conclusions about the safety of higher doses of vancomycin in neonates. Furthermore, the clinical difficulty in ascertaining a diagnosis of sepsis with certainty in neonates makes risk-benefit analyses challenging. The development and use of novel diagnostic biomarkers are likely to improve clinical decision-making and trial design in the years to come [94] . Dose modification based on trough vancomycin concentrations, which are, in turn, largely determined by renal function, adds complexity in determining exposure-toxicity relationships. These issues are probably best addressed with detailed prospective, observational data that define renal impairment according to standardized criteria and allow for a more clinically valid estimation of risk.
Ototoxicity appears rare in patients of all ages treated with vancomycin. Diagnostic OAE and ABR may detect subtle high-frequency hearing loss following vancomycin exposure. These tests can only reliably be carried out in babies above 34 weeks, before which many preterm neonates will already have receive courses of vancomycin. UNHS at term is unlikely to detect subtle hearing impairment and identify exposure-toxicity relationships. Prospective studies that use robust and standardized definitions of hearing impairment based on diagnostic testing, such as with visual reinforcement audiometry at 8-12 months, are needed to further clarify the risk of clinically significant ototoxicity.
